Evaxion A/S American Depositary Share (EVAX)

FairStock Score: 25/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-style investor, I start with what is knowable. Evaxion is a 46-employee clinical-stage biotech chasing AI-designed immunology vaccines; the lead assets are in Phase 2 and Phase 1. That is not a business with a durable moat yet—it is a research pipeline whose value depends on trial outcomes and financing. On 2026-10-13, the shares closed at $2.76, giving a market cap of $35.3 million. FairStock calculations show a negative P/E of -5.52, a P/B of 2.42, ROE of -109.86%, ROCE of -25.97%, and D/E of 0.75. Its Piotroski score is 4/9 and Altman Z-score is -5.81, suggesting weak financial strength. The FairStock Score is 25/100, and no Lynch category applies because there are only 0 years of filed results versus the required three. The one bright spot: in 2025-Q3, revenue was $7.5 million, net income $4.6 million, and margin 61.64%. But a single profitable quarter does not offset a negative earnings history, negative returns on capital, and the need for continued R&D spending. Revenue growth is N/A, profit growth is 22.81%, and beta is 0.27. The 52-week range of $2.72-$11.51 shows how volatile sentiment has been. Without a margin of safety in hard assets or stable earnings, I would treat this as a speculative pipeline, not a classic value investment.

In plain English: Evaxion is a tiny biotech that uses artificial intelligence to design vaccines for cancer and other diseases. The business looks weak overall: it has negative earnings, poor profitability, and signs of financial strain, though it just posted a profitable 2025 third quarter with $7.5 million in revenue and $4.6 million in net income. At $2.76, the price looks speculative relative to those mixed numbers rather than clearly cheap or fairly priced.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer